Golumbeski George
Director at ENTA
- Sold, on record
- $2.2M
- Dollars the filings state
- Form 4 sales
- 2
- Latest Mar 4, 2019
- Form 144 notices
- 0
- Proposed sales
- Quarters with a sale
- 0 of the last 8
- No sale in two years
- Companies
- 1
- Filed as an executive or holder
Companies
- ENTAENANTA PHARMACEUTICALS INCDirector
Sales by reason
0
Routine
0
Plan not stated
0
No plan
2
Unusual
Form 4 sales per year, every sale on record.
Timeline
- Mar 4, 2019Unusual
Sold 100% of their holdings
$962k9,280 shares at $103.65
- Feb 12, 2019Unusual
Sold 100% of their holdings
$1.2M13,500 shares at $90.06
2 of 2
Every transaction
| Traded | Filed | Stock | Role | What | Amount | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|---|---|
| Jun 3, 2026 | Jun 5, 2026 | ABOS | Director | AwardedStock Option (right to buy) | 53,250 | 53,250 | SEC | ||
| Jun 3, 2026 | Jun 5, 2026 | ABOS | Director | Awarded | 35,500 | 35,500 | SEC | ||
| May 29, 2026 | Jun 2, 2026 | STTK | Director | AwardedStock Option (Right to Buy) | 81,000 | 81,000 | SEC | ||
| Dec 5, 2025 | Dec 5, 2025 | MURA | Director | Returned to the companyStock Option (right to buy) | 23,971 | 0 | SEC | ||
| Nov 6, 2025 | Nov 10, 2025 | ABOS | Director | AwardedStock Option (right to buy) | 50,000 | 50,000 | SEC | ||
| Jul 31, 2025 | Jul 31, 2025 | Sage Therapeutics, Inc. | Director | Tendered | 8,000 | 0 | SEC | ||
| Jul 31, 2025 | Jul 31, 2025 | Sage Therapeutics, Inc. | Director | Returned to the companyStock Option (Right to Buy) | 35,093 | 0 | SEC | ||
| Jul 14, 2025 | Jul 16, 2025 | STTK | Director | AwardedStock Option (Right to Buy) | 33,150 | 33,150 | SEC | ||
| Jun 11, 2025 | Jun 13, 2025 | Sage Therapeutics, Inc. | Director | AwardedStock Option (Right to Buy) | 21,500 | 21,500 | SEC | ||
| Jun 11, 2025 | Jun 13, 2025 | MURA | Director | AwardedStock Option (right to buy) | 8,637 | 8,637 | SEC | ||
| Jan 3, 2025 | Jan 6, 2025 | Sage Therapeutics, Inc. | Director | AwardedStock Options (Right to buy) | 13,593 | 13,593 | SEC | ||
| Jul 30, 2024 | Jul 31, 2024 | MURA | Director | AwardedStock Option (right to buy) | 15,334 | 15,334 | SEC | ||
| Jun 21, 2024 | Jun 21, 2024 | STTK | Director | AwardedStock Option (Right to Buy) | 27,700 | 27,700 | SEC | ||
| Jun 10, 2024 | Jun 11, 2024 | Sage Therapeutics, Inc. | Director | AwardedStock Option (Right to Buy) | 12,500 | 12,500 | SEC | ||
| Jan 3, 2024 | Jan 4, 2024 | Sage Therapeutics, Inc. | Director | AwardedStock Options (Right to buy) | 3,495 | 3,495 | SEC | ||
| Jun 15, 2023 | Jun 16, 2023 | Sage Therapeutics, Inc. | Director | AwardedStock Option (Right to Buy) | 10,000 | 10,000 | SEC | ||
| May 26, 2023 | May 31, 2023 | STTK | Director | AwardedStock Option (Right to Buy) | 40,258 | 40,258 | SEC | ||
| Jan 4, 2023 | Jan 5, 2023 | Sage Therapeutics, Inc. | Director | AwardedStock Options (Right to buy) | 2,108 | 2,108 | SEC | ||
| Jun 16, 2022 | Jun 17, 2022 | Sage Therapeutics, Inc. | Director | AwardedStock Option (Right to Buy) | 9,947 | 9,947 | SEC | ||
| Jun 8, 2022 | Jun 10, 2022 | STTK | Director | AwardedStock Option (Right to Buy) | 40,258 | 40,258 | SEC | ||
| May 5, 2022 | May 9, 2022 | Sage Therapeutics, Inc. | Director | Bought | 8,000 | $31.45 | $252k | 8,000 | SEC |
| Apr 26, 2022 | Apr 27, 2022 | STTK | Director | Bought | 28,330 | $3.63 | $103k | 54,613 | SEC |
| Apr 22, 2022 | Apr 26, 2022 | STTK | Director | Bought | 26,283 | $3.69 | $97k | 26,283 | SEC |
| Jan 4, 2022 | Jan 5, 2022 | Sage Therapeutics, Inc. | Director | AwardedStock Options (Right to buy) | 1,638 | 1,638 | SEC | ||
| Jun 19, 2021 | Jun 22, 2021 | STTK | Director | AwardedStock Option (Right to Buy) | 3,434 | 3,434 | SEC | ||
| Jun 10, 2021 | Jun 11, 2021 | Sage Therapeutics, Inc. | Director | AwardedStock Option (Right to Buy) | 10,000 | 10,000 | SEC | ||
| Jan 5, 2021 | Jan 6, 2021 | Sage Therapeutics, Inc. | Director | AwardedStock Options (Right to buy) | 832 | 832 | SEC | ||
| Dec 22, 2020 | Dec 28, 2020 | STTK | Director | AwardedStock Option (Right to Buy) | 1,286 | 1,286 | SEC | ||
| Jul 6, 2020 | Jul 8, 2020 | CRBP | Director | AwardedStock Option(right to buy) | 81,000 | 81,000 | SEC | ||
| Jun 9, 2020 | Jun 11, 2020 | Sage Therapeutics, Inc. | Director | AwardedStock Option (Right to Buy) | 10,000 | 10,000 | SEC | ||
| Feb 26, 2020 | Feb 28, 2020 | ENTA | Director | AwardedStock Option (right to buy) | 10,000 | 10,000 | SEC | ||
| Jan 3, 2020 | Jan 7, 2020 | Sage Therapeutics, Inc. | Director | AwardedStock Options (Right to buy) | 976 | 976 | SEC | ||
| Jun 5, 2019 | Jun 6, 2019 | Sage Therapeutics, Inc. | Director | AwardedStock Option (Right to Buy) | 10,000 | 10,000 | SEC | ||
| Mar 4, 2019 | Mar 6, 2019 | ENTA | Director | Sold | 9,280 | $103.65 | $962k | 0 | SEC |
| Mar 4, 2019 | Mar 6, 2019 | ENTA | Director | Exercised or settledStock Option (Right to Buy) | 9,280 | 0 | SEC | ||
| Mar 4, 2019 | Mar 6, 2019 | ENTA | Director | Exercised options | 9,280 | $36.61 | $340k | 9,280 | SEC |
| Feb 28, 2019 | Mar 1, 2019 | ENTA | Director | AwardedStock Option (right to buy) | 5,000 | 5,000 | SEC | ||
| Feb 12, 2019 | Feb 13, 2019 | ENTA | Director | Sold | 13,500 | $90.06 | $1.2M | 0 | SEC |
| Feb 12, 2019 | Feb 13, 2019 | ENTA | Director | Exercised or settledStock Option (Right to Buy) | 13,500 | 0 | SEC | ||
| Feb 12, 2019 | Feb 13, 2019 | ENTA | Director | Exercised options | 13,500 | $27.49 | $371k | 11,228 | SEC |
| Jan 22, 2019 | Jan 24, 2019 | Sage Therapeutics, Inc. | Director | AwardedStock Options (Right to buy) | 20,000 | 20,000 | SEC | ||
| Feb 28, 2018 | Mar 5, 2018 | ENTA | Director | AwardedStock Option (right to buy) | 7,500 | 7,500 | SEC | ||
| Feb 16, 2017 | Feb 21, 2017 | ENTA | Director | AwardedStock Option (right to buy) | 7,500 | 7,500 | SEC | ||
| Feb 11, 2016 | Feb 12, 2016 | ENTA | Director | AwardedStock Option (right to bury) | 6,000 | 6,000 | SEC | ||
| Feb 19, 2015 | Feb 20, 2015 | ENTA | Director | AwardedStock Option (right to bury) | 6,000 | 6,000 | SEC | ||
| Feb 7, 2014 | Feb 11, 2014 | ENTA | Director | AwardedStock Option (right to bury) | 9,280 | 9,280 | SEC |